14th week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140094448 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS - The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula: | 2014-04-03 |
20140094449 | TREATMENT OF BIPOLAR DISORDER - The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt thereof; Formula (I); in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C | 2014-04-03 |
20140094450 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS - The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, | 2014-04-03 |
20140094451 | PREVENTIVE OR REMEDY FOR GLAUCOMA - There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an α | 2014-04-03 |
20140094452 | Rapid Onset Liquid Midazolam Composition for Buccal Administration - This application discloses liquid compositions for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is about 6 or higher, the composition comprises less than about 200 mg/ml cyclodextrin, and at least about 50% of the midazolam is present in solution. Uses of these compositions are also disclosed. | 2014-04-03 |
20140094453 | SWEET FLAVOR MODIFIER - The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of modulating the sweet taste of compositions. | 2014-04-03 |
20140094454 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides compounds of Formula I: | 2014-04-03 |
20140094455 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE - Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins. | 2014-04-03 |
20140094456 | ANTI-FIBROTIC PYRIDINONES - Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders. | 2014-04-03 |
20140094457 | PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF GENETIC DISEASES ASSOCIATED WITH NONSENSE MEDIATED RNA DECAY - The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in a subject. Also disclosed is a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy. The present invention also relates to a method of identifying inhibitors of nonsense mediated RNA decay and/or inducing autophagy. The present invention further relates to a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy in a subject. | 2014-04-03 |
20140094458 | Cyclic Progestin Regimens and Kits - A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen. | 2014-04-03 |
20140094459 | Tyrosine Kinase Inhibitors - The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 2014-04-03 |
20140094460 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula I: | 2014-04-03 |
20140094461 | BIOMARKERS FOR HEDGEHOG INHIBITOR THERAPY - A method of selecting a subject having cancer for treatment with a Hedgehog signaling inhibitor by determining the level of expression of at least one biomarker in a biological sample derived from the subject. | 2014-04-03 |
20140094462 | SONIC HEDGEHOG MODULATORS - Sonic Hedgehog modulators and methods of use thereof are provided for. | 2014-04-03 |
20140094463 | Pharmaceutical Compositions - The present invention relates to carrier systems useful for pharmaceutical compositions. These carriers comprise an emulsifier, and also in further embodiments a polymeric dissolution aid. These carriers are useful for delivering pharmaceutical actives such as antimicrobial agents. | 2014-04-03 |
20140094464 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES - The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases. | 2014-04-03 |
20140094465 | Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2014-04-03 |
20140094466 | SSH-2 (SLINGSHOT-2) INHIBITORS AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment compositions of the invention slow or inhibit F-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit, or reverse, or ameliorate the progression of a cancer or a metastasis or other uncontrolled or unregulated cell growth, and/or Alzheimer's disease. | 2014-04-03 |
20140094467 | METHOD AND COMPOSITION FOR MODULATING CANONICAL WNT PATHWAY USING FOLATE AND INOSITOL - The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect. | 2014-04-03 |
20140094468 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof - The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents. | 2014-04-03 |
20140094469 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 2014-04-03 |
20140094470 | COMBINATION TREATMENT FOR DERMATOLOGICAL CONDITIONS - The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier. | 2014-04-03 |
20140094471 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2014-04-03 |
20140094472 | PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES - The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment. | 2014-04-03 |
20140094473 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 2014-04-03 |
20140094474 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES - Compounds of formula (I) or (II) | 2014-04-03 |
20140094475 | SOLID FORMS OF ANTIRETROVIRAL COMPOUNDS, PROCESS FOR THE PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION THEREOF - Disclosed are solid forms of antiretroviral compounds and anti-oxidative acids, and processes for their preparation. Pharmaceutical compositions using the solid forms are also disclosed. | 2014-04-03 |
20140094476 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYL- PROPANENITRILE - The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2014-04-03 |
20140094477 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYL- PROPANENITRILE - The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2014-04-03 |
20140094478 | COMPOSITION AND TABLET COMPRISING RALTEGRAVIR - The present invention relates to a composition and tablet comprising raltegravir and to a process for the preparation of such tablet. | 2014-04-03 |
20140094479 | Process For Producing A Solid Dispersion Of An Active Ingredient - A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( | 2014-04-03 |
20140094480 | Pro-Neurogenic Compounds - This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death. | 2014-04-03 |
20140094481 | TAMPER RESISTANT DOSAGE FORMS - Tamper resistant controlled release formulations. | 2014-04-03 |
20140094482 | BENZAZOCINE-RING COMPOUND INHIBITION OF TAU HYPERPHOSPHORYLATION - A method of inhibiting hyperphosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a FLNA-binding effective amount of a FLNA-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1. The administered compound preferably contains at least four of the six pharmacophores of FIGS. | 2014-04-03 |
20140094483 | NOVEL ISO-ERGOLINE DERIVATIVES - Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2014-04-03 |
20140094484 | SUSTAINED DELIVERY FORMULATIONS OF RAPAMYCIN COMPOUNDS - The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative. | 2014-04-03 |
20140094485 | SOLID STATE FORMS OF HIV INHIBITOR - The invention relates to a novel hemi-succinate salt form of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid and a novel crystalline form thereof, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection. | 2014-04-03 |
20140094486 | SOLID STATE FORMS OF HIV INHIBITOR - The invention relates to novel crystalline forms of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, the hydrochloride salt thereof, novel crystalline forms of the hydrochloride salt, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection. | 2014-04-03 |
20140094487 | Dihydro-6-Azaphenalene Derivatives for the Treatment of CNS, Oncological Diseases and Related Disorders - In one embodiment, the present application discloses 2-aza-, 2-oxa- and 2-thia-2,3-dihydro-6-azaphenalene compounds and compositions, and methods for treating a neurological disease in a patient in need thereof using the compounds and compositions as disclosed herein. | 2014-04-03 |
20140094488 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS - The invention relates to the compounds of general formula (I): Preparation process and therapeutic use. | 2014-04-03 |
20140094489 | HETEROCYCLIC CARBOXYLIC ACID ESTER DERIVATIVE - The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I) | 2014-04-03 |
20140094490 | ANTI-NEURODEGENERATIVE DISEASE AGENT - The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: | 2014-04-03 |
20140094491 | DIMETHYL-BENZOIC ACID COMPOUNDS - The present invention provides a compound of the Formula II: | 2014-04-03 |
20140094492 | DERIVATIVES OF SULINDAC, USE THEREOF AND PREPARATION THEREOF - Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided. | 2014-04-03 |
20140094493 | Novel Ether Linked Compounds and Improved Treatments for Cardiac and Cardiovascular Disease - A compound of Formula (I), and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: | 2014-04-03 |
20140094494 | Antifungal Treatment - A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is compound 13 or 33 and is combined with an azole compound, such as fluconazole. | 2014-04-03 |
20140094495 | Antimicrobial Haloalkyl Heterocycle Compounds - This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents. | 2014-04-03 |
20140094496 | FORMULATIONS OF BENDAMUSTINE - Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations. | 2014-04-03 |
20140094497 | Angiotensin in Treating Brain Conditions - The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration. | 2014-04-03 |
20140094498 | METHODS AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN COMPRISING CLONIDINE - The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days. | 2014-04-03 |
20140094499 | FORMULATIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPRO- PAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE - The present invention relates to formulations of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), pharmaceutical packs or kits thereof, and methods of treatment therewith. | 2014-04-03 |
20140094500 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD - Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy. | 2014-04-03 |
20140094501 | SiRNA Sequence-Independent Modification Formats for Reducing Off-Target Phenotypic Effects in RNAi, and Stabilized Forms Thereof - Modification formats having modified nucleotides are provided for siRNA. Short interfering RNA having modification formats and modified nucleotides provided herein reduce off-target effects in RNA interference of endogenous genes. Further modification formatted siRNAs are demonstrated to be stabilized to nuclease-rich environments. Unexpectedly, increasing or maintaining strand bias, while necessary to maintain potency for endogenous RNA interference, is not sufficient for reducing off-target effects in cell biology assays. | 2014-04-03 |
20140094502 | RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERS - RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention. | 2014-04-03 |
20140094503 | RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of IDH1 and mutant IDH1 gene expression and/or activity, and/or modulate an IDH1 or mutant IDH1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules, including small nucleic acid molecules such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, that are capable of mediating or that mediate RNA interference (RNAi) against IDH1 or mutant IDH1 gene expression. | 2014-04-03 |
20140094504 | HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF - Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9. | 2014-04-03 |
20140094505 | BIOMARKERS FOR ASSESSING TREATMENT OF SIALIC ACID DEFICIENCY DISEASES AND CONDITIONS - The present invention relates to methods of monitoring and assessing sialic acid deficiency treatment as well as to methods of predicting/determining responsiveness to treatment for a sialic acid deficiency using biomarkers. Sialic acid deficiencies include for example Hereditary Inclusion Body Myopathy (HIBM). | 2014-04-03 |
20140094506 | USE OF LIGHT SENSITIVE GENES - The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells. | 2014-04-03 |
20140094507 | MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF - The present invention provides compounds and compositions that can modulate formation of Toll-like receptor 3 (TLR3) and double-stranded RNA (dsRNA) complex, and methods for using the same. In particular, some aspects of the invention provide compounds of the formula: | 2014-04-03 |
20140094508 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE - Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases. | 2014-04-03 |
20140094509 | NON-AQUEOUS TAXANE NANODISPERSION FORMULATIONS AND METHODS OF USING THE SAME - Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations. Non-aqueous, ethanol-free docetaxel nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations. | 2014-04-03 |
20140094510 | NON-AQUEOUS TAXANE NANODISPERSION FORMULATIONS AND METHODS OF USING THE SAME - Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are non-aqueous, ethanol-free docetaxel nanodispersion formulations. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations. | 2014-04-03 |
20140094511 | Treatment of Obstructive Sleep Apnea Syndrome with a Combination of a Carbonic Anhydrase Inhibitor and an Additional Active Agent - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 2014-04-03 |
20140094512 | METHOD OF MODULATING THE DEGREE OF ADIPOSE TISSUE DEPOSITED INTRAMUSCULARLY - The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in cattle by administration of a retinoic receptor antagonist or inverse agonist and compounds for use in such method. | 2014-04-03 |
20140094513 | COMPOSITION AND METHOD FOR NEUROPROTECTION AGAINST EXCITOTOXIC INJURY - The present invention discloses the combined treatment of memantine (N-methyl-D-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea polyphenols in preventing or treating clinical excitotoxic injury such as brain trauma, brain ischemia, epilepsy, and Alzheimer's disease. | 2014-04-03 |
20140094514 | PHARMACEUTICAL AND FOOD COMPOSITIONS FOR PREVENTING OR TREATING DIABETES OR OBESITY - The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the | 2014-04-03 |
20140094515 | COSMETIC PARTICLES THAT TRANSFORM FROM HARD TO SOFT PARTICLES COMPRISING HYDROGENATED LONG-CHAIN TRIGLYCERIDE OILS - Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15% by weight fatty acid moieties with carbon chain lengths of C | 2014-04-03 |
20140094516 | METHOD OF UTILIZING AZELAIC ACID ESTERS TO MODULATE COMMUNICATIONS MEDIATED BY BIOLOGICAL MOLECULES - The treatment of disease in organisms using Macromolecular interaction modulators and Membrane active immunomodulators, particularly selected azelaic acid esters, individually and in combinations, to modulate communications between biological molecules. | 2014-04-03 |
20140094517 | PRESERVATIVE SYSTEM FOR COSMETIC FORMULATIONS- COMPOSITIONS AND METHODS THEREOF - The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of | 2014-04-03 |
20140094518 | METHOD FOR REGULATING RETINAL ENDOTHELIAL CELL VIABILITY - Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathological conditions of retinal endothelial cells associated with radiation retinopathy, diabetic retinopathy and chemotherapy for retinoblastoma. | 2014-04-03 |
20140094519 | LIPOXIN ANALOGS AS NOVEL INHIBITORS OF ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 2014-04-03 |
20140094520 | OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE - Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore. | 2014-04-03 |
20140094521 | BENZYLAMINE DERIVATIVE - The objective of the present invention is to provide a new compound which is effective in treating blood cancer, particularly multiple myeloma, and which is also effective in suppressing an SP cell, i.e. Side Population Cell, which is a cause of recurrence of cancer. The compound according to the present invention is a novel compound which has the specific benzylamine structure. | 2014-04-03 |
20140094522 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS - Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided. | 2014-04-03 |
20140094523 | SOLID AMBROXOL-CONTAINING PREPARATION - The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases. | 2014-04-03 |
20140094524 | ASTAXANTHIN-CONTAINING PET FOODS - There is provided pet food comprising astaxanthin and/or an ester thereof as an active component and having an effect of deodorizing excrement such as urine and feces, effects of improving sleep, sensibility such as perception and cognition, and visual sense, and an effect of treating, improving or preventing diabetes and diabetic complications. The pet food can deodorize excrement such as urine and feces, improve sleep, sensibility such as perception and cognition, and visual sense, and treat, improve or prevent diabetes and diabetic complications. | 2014-04-03 |
20140094525 | FOAMABLE ALCOHOLIC COMPOSITION - A foamable composition is provided that includes at least 40 weight percent alcohol, based upon the total weight of the alcoholic composition; and a foaming surfactant selected from the group consisting of silicone quats. | 2014-04-03 |
20140094526 | pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME - Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia. | 2014-04-03 |
20140094527 | METHOD FOR EXTRACTING AN ODOROUS EXTRACT BY AN ALTERNATIVE SOLVENT TO CONVENTIONAL SOLVENTS - Methods for extracting an extract of volatile odorous compounds from an organic raw material containing odorous compounds is disclosed. The method includes contacting an organic raw material with dimethyl carbonate, as a solvent, in at least one bath at a temperature of 10° C. to 70° C. A liquid organic phase is obtained that includes the dimethyl carbonate charged with volatile odorous compounds and is collected. If the liquid organic phase comprises an immiscible aqueous phase, decanting occurs to separate the dimethyl carbonate charged with odorous compounds therefrom thereby eliminating the aqueous phase. Next, partially eliminating by evaporation forms a pre-concentrated extract of volatile odorous compounds, which is recovered and if water is present, decanting occurs to eliminate the water. Additionally, concentrating the pre-concentrated extract of volatile odorous compounds by evaporation is performed to obtain the extract of volatile odorous compounds. | 2014-04-03 |
20140094528 | OIL-BASED GEL-LIKE COMPOSITION - Provided is a gel-forming agent that is easy to prepare and has all the properties including high safety for the living body and the environment, satisfactory gel-forming capability, comfortable feeling upon use, and good handleability. The gel-forming agent includes a lecithin, and a polyglycerol fatty acid ester in an amount of from 30 to 150 parts by weight per 100 parts by weight of the lecithin. The polyglycerol fatty acid ester has a fatty acid residue having 14 or less carbon atoms, has an HLB of 15 or more as determined based on an organic conceptual diagram, and has a degree of glycerol polymerization of from 8 to 40. | 2014-04-03 |
20140094529 | MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME - Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable. | 2014-04-03 |
20140094530 | POLYURETHANE AND POLYISOCYANURATE RIGID FOAMS FOR ROOFING INSULATION - Polyurethane foams having a NFPA 101 Class B rating (ASTM E-84) which pass the FM 4450 calorimeter Test are produced by reacting: (a) an organic polyisocyanate, (b) at least one polyether polyol or polyester polyol with a nominal hydroxyl functionality of at least 2.0, (c) a blowing agent composition and (d) at least one halogen-free flame retardant. The blowing agent composition includes: (1) no more than 10% by weight, based on total weight of the foam-forming composition, of one or more hydrocarbons having an LEL less than 2% by volume in air, and/or (2) a hydrocarbon having an LEL greater than 2% by volume in air, and (3) up to 1% by weight, based on total weight of foam-forming composition, of water. | 2014-04-03 |
20140094531 | RIGID POLYURETHANE AND POLYISOCYANURATE FOAMS BASED ON FATTY ACID MODIFIED POLYETHERPOLYOLS - A process for producing rigid polyurethane foams or rigid polyisocyanurate foams is provided. The process contains the reaction of polyisocyanate, fatty acid modified polyetherpolyol, polyetherpolyol, optionally flame retardant, blowing agent, catalyst, and optionally further auxiliary and/or admixture agent, wherein the polyetherpolyol is obtained by a process containing reacting orthotolylenediamine and optionally further co-starters with alkylene oxide containing ethylene oxide wherein the ethylene oxide content is more than 20 wt %, and then reacting the reaction product with alkylene oxide containing propylene oxide wherein the 1,2-propylene oxide content is more than 20 wt %, in the presence of a catalyst. | 2014-04-03 |
20140094532 | PROCESS FOR PREPARING POLYDIMETHYLSILOXANES ON SULPHONIC ACID CATION EXCHANGE RESINS - The invention relates to a process for the targeted reorganization of polydimethylsiloxanes over sulphonic acid-containing cation exchange resins which have water contents of 8 to 25% by weight, and polydimethylsiloxanes thus prepared and the use thereof. | 2014-04-03 |
20140094533 | ETHYLENE-BASED POLYMERS AND PROCESSES TO MAKE THE SAME - The invention provides a composition comprising a low density polyethylene (LDPE) obtained by free radical polymerization of ethylene, and wherein the LDPE has a GPC-Viscometer parameter “DPP” less than 1.3. | 2014-04-03 |
20140094534 | Polyurethane Foam Elastomers for High Temperature Applications - Molded elastomeric polyurethane foams suitable for use as gasketing and sealing devices for use in hot environments are disclosed. The foams are the reaction product of an aromatic polyisocyanate with an isocyanate-reactive composition that includes one or more polyether polyols, certain diol chain extenders, and certain low equivalent weight hydroxyl-containing cross-linkers. The molded foams exhibit low compression sets after being compressed and aged at elevated temperatures. | 2014-04-03 |
20140094535 | POLYETHERIMIDE COMPOSITIONS, METHODS OF MANUFACTURE, AND ARTICLES FORMED THEREFROM - A method for the manufacture of a polyetherimide composition includes catalyzing the reaction of a dianhydride and an organic diamine with a catalyst selected from guanadinium salts, pyridinium salts, imidazolium salts, tetra(C | 2014-04-03 |
20140094536 | POLYETHERIMIDE COMPOSITIONS, METHODS OF MANUFACTURE, AND ARTICLES FORMED THEREFROM - A method for the manufacture of a polyetherimide composition includes catalyzing the reaction of a dianhydride and an organic diamine with a catalyst selected from guanadinium salts, pyridinium salts, imidazolium salts, tetra(C | 2014-04-03 |
20140094537 | AQUEOUS POUR POINT DEPRESSANT DISPERSION COMPOSITION - The present invention relates to an aqueous pour point depressant dispersion composition comprising a thermoplastic polymer, preferably ethylene vinyl acetate (EVA); a dispersing agent; water; optionally an aqueous freezing point depressant; and optionally a stabilizing agent wherein the volume average particle size of the dispersed thermoplastic polymer is equal to or less than 1 micrometers and a method to make and use said composition. | 2014-04-03 |
20140094538 | THERMOPLASTIC ELASTOMER COMPOUNDS EXHIBITING SUPERIOR COMPRESSION SET PROPERTIES - A blend of polyisobutylene-based thermoplastic vulcanizate, styrene-ethylene-ethylene-propylene-styrene, low molecular weight liquid polybutene, polyolefin, polyphenylene ether, and, optionally, filler is disclosed which has good processability, lower compression set, and more effective barrier properties for oxygen than the same blend without the styrene-ethylene-ethylene-propylene-styrene and the polyphenylene ether. The blend is superior in oxygen transmission rate properties than a conventional styrenic block copolymer containing thermoplastic elastomer. | 2014-04-03 |
20140094539 | FIRE RESISTANT COATINGS - An intumescent coating composition is disclosed comprising two intumescent agents, a polymer and optionally, one or more ancilliary agents. One of the intumescent agents is expandable graphite, and the other is a melamine cyanurate complex. These two intumescent agents in combination with the polymer, which is flexible and weather resistant, provide a coating composition that will not smoke or distribute burning particles in the wind. | 2014-04-03 |
20140094540 | SUPERHYDROPHOBIC POWDER COATINGS - A superhydrophobic coating, comprises a superhydrophobic powder with superhydrophobic particles having a three dimensional nanostructured surface topology defining pores, and a resin. The superhydrophobic particles are embedded within the resin and the resin does not fill the pores of the superhydrophobic particles such that the three dimensional surface topology of the superhydrophobic particles is preserved. A precursor powder for a superhydrophobic coating and a method for applying a superhydrophobic coating to a surface are also disclosed. | 2014-04-03 |
20140094541 | COMPOSITE MATERIALS FORMED BY SHEAR MIXING OF CARBON NANOSTRUCTURES AND RELATED METHODS - Carbon nanostructures free of an adhered growth substrate can include a plurality of carbon nanotubes that are branched, crosslinked, and share common walls with one another. Under applied shear, crosslinks between the carbon nanotubes in carbon nanostructures can break to form fractured carbon nanotubes that are branched and share common walls. Methods for making polymer composites from carbon nanostructures can include combining a polymer matrix and a plurality of carbon nanostructures that are free of an adhered growth substrate, and dispersing the carbon nanostructures in the polymer matrix under applied shear. The applied shear breaks crosslinks between the carbon nanotubes to form a plurality of fractured carbon nanotubes that are dispersed as individuals in the polymer matrix. Polymer composites can include a polymer matrix and a plurality of fractured carbon nanotubes dispersed as individuals in the polymer matrix. | 2014-04-03 |
20140094542 | PROCESS FOR PRODUCING PROTECTIVE COLLOID-STABILIZED POLYMERS - The invention relates to processes for producing protective colloid-stabilized polymers based on (meth)acrylate esters in the form of their aqueous dispersions and water-redispersible polymer powders by means of free-radically initiated emulsion polymerization of one or more monomers from the group consisting of the esters of acrylic acid or methacrylic acid and optionally one or more further monomers which are copolymerizable therewith, in the presence of one or more protective colloids, and optionally drying of the resulting aqueous dispersion, characterized in that the emulsion polymerization is carried out in the presence of one or more fully hydrolysed 1-alkylvinyl ester-vinyl ester copolymers as protective colloid. | 2014-04-03 |
20140094543 | Manufacture and use of a composite material comprising fibres and at least one vinyl chloride polymer - Process for manufacturing a composite material comprising fibres and at least one vinyl chloride polymer comprising the immersion of the fibres in a hydrosol of said polymer in order to obtain fibres coated with said hydrosol followed by the drying and gelling of said hydrosol coated on the fibres. Composite material and use thereof for forming articles or for manufacturing reinforcing objects. Profiles reinforced by this composite material. | 2014-04-03 |
20140094544 | PLASTICIZER, A BIODEGRADABLE MATERIAL COMPRISING THE PLASTICIZER AND APPLICATION THEREOF - The present embodiment relates to a Plasticizer, which is fabricated by mixing monomers of biodegradable polymer with bio-molecules subsequently to deal the mixture with thermal treatment. The Biodegradable material comprising the Plasticizer has high melt index which is contributive for the processing of thermal processing, and the microwave-tolerance and water-resistance of the material makes the material suitable for food packaging. | 2014-04-03 |
20140094545 | ENHANCED POLYCARBONATE EXTRUSION GRADES - The present disclosure relates to thermoplastic compositions, methods of making thermoplastic compositions, and articles made from thermoplastic compositions. The disclosed compositions comprise a polycarbonate polymer and a triacylglyceride release agent. In an embodiment, a thermoplastic composition comprising: a melt polycarbonate polymer; and 0.01 to 0.05 weight percent of a release agent based on the total weight of the composition, wherein the release agent comprises triacylglyceride, and wherein the composition is free of stearyl stearate, glycerol monostearate, and pentaerythrityl tetrastearate. | 2014-04-03 |
20140094546 | FLUOROPOLYMER COATINGS - The present invention relates to a fluoropolymer coating having improved tribological properties, which coating comprises nanodiamond particles in a concentration between 0.01 wt. % and 5 wt. %, wherein said fluoropolymer coating is obtained by drying and curing a slurry composition comprising said fluoropolymer and said nanodiamond particles, wherein the zeta potential of the nanodiamond particles is over −30 mV at pH higher than 8. The invention also relates to a slurry composition which can be used for producing said fluoropolymer coating. | 2014-04-03 |
20140094547 | REINFORCED HDPE COMPOUNDS WITH IMPROVED MECHANICAL PROPERTIES AND METHODS OF MAKING SAME - A thermoplastic polyolefin composition comprising, based on the total mass of the composition, 10-75% by mass of high density polyethylene (HDPE), 8-30% by mass of elastomer, and 5-45% by mass of filler, wherein the composition has a Melt Flow Rate of 1.0-20 g/10 min according to ISO 1133 at 190° C./2.16 kg. The thermoplastic polyolefin composition is produced in a method comprising batch mixing or continuous mixing the HDPE, elastomer, and filler to form a melt blend, and cooling the melt blend to give the product. In addition, the thermoplastic polyolefin composition can be injection molded to form an article, which is preferably an automotive body part. The thermoplastic polyolefin composition exhibits improved heat deflection temperatures, improved ductile failure mode in low temperature atmosphere, improved flexural modulus and lower specific cost compared to polypropylene based thermoplastic polyolefin compositions. | 2014-04-03 |